1. MJFF Strategy for Accelerating Development of Parkinsonâs Therapies Research Roundtable Chicago, Illinois June 27, 2011
2. Todayâs Agenda MJFF Overview Deborah W. Brooks The Michael J. Fox Foundation for Parkinsonâs Research MJFF Program Highlights Sonal S. Das, PhD The Michael J. Fox Foundation for Parkinsonâs Research Panelists Christopher G. Goetz, MD Rush University Medical Center Jeffrey H. Kordower, PhD Rush University Medical Center Tanya Simuni, MD Northwestern University Glenn T. Stebbins, PhD Rush University Medical Center Questions & Answers Session 2
3. 3 MJFF Overview Deborah W. Brooks Co-Founder/Executive Vice Chairman The Michael J. Fox Foundation for Parkinsonâs Research
4. Parkinsonâs disease: Defining the need Parkinsonâs disease (PD) is a progressive neurodegenerative disease that affects nearly one million Americans; related Parkinsonisms affect an additional half million Americans. PD prevalence is expected to grow sizably over the next 25 years as the proportion of older Americans continues to increase. Significant therapeutic needs exist: Current therapies to treat motor and non-motor symptoms are inadequate leaving substantial unmet needs for those living with PD. There is currently no therapy proven to modify the progression of the disease. 4
5. MJFF was founded with clear objectives Drive the Best Parkinsonâs Research Deliver Improved Therapies and a Cure 5
11. We are not a bank, assets must be deployed quickly to the best science
12.
13. Strategy must focus on tackling roadblocks to progress in a systemic fashion, i.e. target validation, research tools, clinical trial design, recruitment
24. 10 2011 MJFF Program Highlights Need for Disease-Modifying Therapies Biomarkers and The Parkinsonâs Progression Markers Initiative Improving Symptomatic Treatments Sonal S. Das, PhD Associate Director, Research Programs The Michael J. Fox Foundation for Parkinsonâs Research
26. Altering the course of PD: Need for Disease-Modifying Therapies 12 MJFF has committed over $100M to advance disease modifying therapies and seeks a path forward to patients.
27. Expert Insight, Jeffrey H. Kordower, PhD 13 Disease-Modifying Therapies Jeffrey H. Kordower, PhD Director, Research Center for Brain Repair The Jean-SchweppeArmour Professor of Neurological Sciences Rush University Medical Center
31. There are no biological indications of underlying disease that complement clinical changesMarkers of progression are essential to achieve near-term hopes for needed therapies Challenges remain in testing disease-modifying therapies
32.
33. Assist with patient selection for clinical studiesâŚAre we studying the right population of people?
34. Facilitate measurement of modifications in the disease - could provide valid clinical trial endpoints
35. Help guide clinical trial design parameters like patient numbers, stratification, duration of treatment
37. Is the therapeutic having its desired effect?Without markers of progression, clinical trials to test new therapies in patients are at risk of yielding inconclusive results 15
40. A study of this size â $45M over a 5 year period â requires large scale funding: Abbott, Biogen Idec, Covance, GE Healthcare, Genentech, Merck, Pfizer and Roche are lead industry supporters.
41.
42.
43.
44. Breakthroughs in treating dyskinesia would expand options for treating PDMJFF is funding two parallel tracks in dyskinesia research: Developing new therapies Determining how to best assess these therapies in the clinic (Dyskinesia Rating Scale Study)
45. Expert Insight: Christopher G. Goetz, MD 19 Advancing Treatments for Dyskinesia Christopher G. Goetz, MD Professor of Neurological Sciences Professor of Pharmacology Rush University Medical Center Co-Principal Investigator, Dyskinesia Rating Scale Glenn T. Stebbins, PhD Professor of Neurological Sciences Rush University Medical Center Co-Principal Investigator, Dyskinesia Rating Scale
46.
47. 85% of clinical trials finish late due to recruitment troubles
48. Estimates hold that fewer than 1 in 10 people with Parkinsonâs participate in clinical trialsEmpowered coordinators Smart matches Active alert system Robust content 20
49.
50. Sonal S. Das, PhD The Michael J. Fox Foundation for Parkinsonâs Research
55. 22 Thank you for your participation! For more information, please visit: www.michaeljfox.org Our 2011 Research Roundtable Series is generously supported through an educational grant from Teva Neuroscience